Additional Information
Book Details
Abstract
This issue of Medical Clinics of North America, guest edited by Roy Colven, MD, is devoted to Dermatology. Articles in this issue include: Topical Therapy Primer for the Non-dermatologist; The Role of Biologic Therapies in Dermatology; Commonly Used Non-biologic Systemic Therapies in Dermatology; Diseases of Skin Appendages: Acne, Alopecia, and Hyperhidrosis; Common Procedures in Dermatology; Skin Cancer Epidemiology, Detection, and Management; Psoriasis and Cardiovascular Disease; Cutaneous Adverse Drug Reactions; Consultative Inpatient Dermatology; Approach to the Patient with Diffuse Blisters; Teledermatology; Nail Disease for the Primary Care Provider; Rheumatologic Skin Disease; and Common Pediatric Skin Diseases.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Dermatology | i | ||
| Copyight \r | ii | ||
| PROGRAM OBJECTIVE | iii | ||
| TARGET AUDIENCE | iii | ||
| LEARNING OBJECTIVES | iii | ||
| ACCREDITATION | iii | ||
| DISCLOSURE OF CONFLICTS OF INTEREST | iii | ||
| UNAPPROVED/OFF-LABEL USE DISCLOSURE | iii | ||
| TO ENROLL | iv | ||
| METHOD OF PARTICIPATION | iv | ||
| CME INQUIRIES/SPECIAL NEEDS | iv | ||
| MEDICAL CLINICS OF NORTH AMERICA\r | v | ||
| FORTHCOMING ISSUES | v | ||
| January 2016 | v | ||
| March 2016 | v | ||
| May 2016 | v | ||
| RECENT ISSUES | v | ||
| September 2015 | v | ||
| July 2015 | v | ||
| May 2015 | v | ||
| Contributors | vii | ||
| CONSULTING EDITORS | vii | ||
| EDITOR | vii | ||
| AUTHORS | vii | ||
| Contents | xi | ||
| Foreword: Dermatology\r | xi | ||
| Preface: Dermatology \r | xi | ||
| Topical Therapy Primer for Nondermatologists\r | xi | ||
| The Role of Biologic Therapies in Dermatology\r | xi | ||
| Selected Disorders of Skin Appendages—Acne, Alopecia, Hyperhidrosis\r | xi | ||
| Nail Disease for the Primary Care Provider\r | xi | ||
| Psoriasis and Cardiovascular Disease\r | xii | ||
| Clinical Approach to Diffuse Blisters\r | xii | ||
| Atopic Dermatitis: A Common Pediatric Condition and Its Evolution in Adulthood\r | xii | ||
| Rheumatologic Skin Disease\r | xii | ||
| Common Dermatologic Procedures\r | xiii | ||
| Skin Cancer Epidemiology, Detection, and Management\r | xiii | ||
| Approach to the Patient with a Suspected Cutaneous Adverse Drug Reaction\r | xiii | ||
| Inpatient Consultative Dermatology\r | xiii | ||
| Teledermatology\r | xiv | ||
| Foreword: Dermatology\r | xv | ||
| REFERENCES | xvi | ||
| Preface: Dermatology\r | xvii | ||
| Topical Therapy Primer for Nondermatologists | 1167 | ||
| Key points | 1167 | ||
| INTRODUCTION | 1167 | ||
| I: TOPICAL MEDICATIONS | 1167 | ||
| Topical Steroids | 1167 | ||
| Topical Antimicrobials | 1168 | ||
| Topical Acne, Rosacea, and Psoriasis Medications | 1168 | ||
| Topicals for Actinic Keratoses and Nonmelanoma Skin Cancers | 1169 | ||
| II: CASES | 1169 | ||
| Case 1 | 1169 | ||
| Case 2 | 1175 | ||
| Case 3 | 1177 | ||
| Case 4 | 1178 | ||
| Case 5 | 1179 | ||
| Case 6 | 1179 | ||
| SUMMARY | 1181 | ||
| REFERENCES | 1181 | ||
| The Role of Biologic Therapies in Dermatology | 1183 | ||
| Key points | 1183 | ||
| INTRODUCTION | 1183 | ||
| TUMOR NECROSIS FACTOR INHIBITORS | 1184 | ||
| INTERLEUKIN-12/INTERLEUKIN-23 INHIBITION | 1187 | ||
| INTERLEUKIN-17 INHIBITORS | 1188 | ||
| RITUXIMAB | 1188 | ||
| INTRAVENOUS IMMUNOGLOBULIN | 1190 | ||
| SUMMARY | 1191 | ||
| REFERENCES | 1191 | ||
| Selected Disorders of Skin Appendages—Acne, Alopecia, Hyperhidrosis | 1195 | ||
| Key points | 1195 | ||
| INTRODUCTION | 1195 | ||
| HYPERHIDROSIS | 1197 | ||
| Topical Treatments | 1198 | ||
| Oral Treatments | 1198 | ||
| Iontophoresis | 1199 | ||
| Botulinum Toxin | 1199 | ||
| Surgical Treatments | 1199 | ||
| ACNE | 1200 | ||
| Comedonal Acne | 1201 | ||
| Inflammatory Acne | 1202 | ||
| Nodulocystic Acne | 1203 | ||
| Hormonal Treatments | 1203 | ||
| ALOPECIA | 1204 | ||
| Alopecia Areata | 1205 | ||
| Androgenetic Alopecia/Female Pattern Hair Loss | 1207 | ||
| Telogen Effluvium | 1209 | ||
| SUMMARY | 1210 | ||
| REFERENCES | 1210 | ||
| Nail Disease for the Primary Care Provider | 1213 | ||
| Key points | 1213 | ||
| INTRODUCTION | 1213 | ||
| INFECTIONS OF THE NAIL UNIT | 1213 | ||
| Onychomycosis | 1213 | ||
| Pseudomonal Nail Infection | 1217 | ||
| Acute Paronychia | 1217 | ||
| Periungual Verrucae | 1218 | ||
| INFLAMMATORY DERMATOSES OF THE NAIL UNIT | 1219 | ||
| Psoriasis | 1219 | ||
| Lichen Planus | 1220 | ||
| Alopecia Areata | 1221 | ||
| Chronic Paronychia | 1221 | ||
| NAIL UNIT NEOPLASMS | 1221 | ||
| Longitudinal Melanonychia | 1221 | ||
| Longitudinal Erythronychia | 1222 | ||
| Subungual Exostosis | 1222 | ||
| Digital Mucous Cyst | 1223 | ||
| SUMMARY | 1223 | ||
| REFERENCES | 1223 | ||
| Psoriasis and Cardiovascular Disease | 1227 | ||
| Key points | 1227 | ||
| INTRODUCTION | 1227 | ||
| PREVALENCE OF CARDIOVASCULAR COMORBIDITIES | 1228 | ||
| Environmental Risk Factors | 1228 | ||
| The Metabolic Syndrome | 1228 | ||
| Obesity | 1228 | ||
| Dyslipidemia | 1228 | ||
| Hypertension | 1229 | ||
| Diabetes mellitus | 1229 | ||
| Microvascular Disease | 1229 | ||
| Macrovascular and Cardiac Complications | 1229 | ||
| Venous thromboembolism | 1229 | ||
| Peripheral arterial disease | 1230 | ||
| Coronary artery disease and myocardial infarction | 1230 | ||
| Cardiomyopathy | 1230 | ||
| Atrial fibrillation and cerebrovascular disease | 1230 | ||
| PATHOPHYSIOLOGIC MECHANISMS AND BIOMARKERS | 1231 | ||
| EFFECT OF PSORIASIS THERAPIES ON CARDIOVASCULAR OUTCOMES | 1232 | ||
| Nonbiologic Systemic Therapies | 1232 | ||
| Biologic Therapies | 1233 | ||
| Tumor Necrosis Factor-α Inhibitors | 1233 | ||
| Interleukin-12/23 inhibitors | 1233 | ||
| SCREENING AND TREATMENT OF RISK FACTORS | 1233 | ||
| SUMMARY | 1234 | ||
| REFERENCES | 1234 | ||
| Clinical Approach to Diffuse Blisters | 1243 | ||
| Key points | 1243 | ||
| PATIENT HISTORY | 1245 | ||
| PHYSICAL EXAMINATION | 1245 | ||
| DIAGNOSTIC TESTING | 1246 | ||
| BLISTERING CONDITIONS CAUSED BY EXTERNAL TRIGGERS | 1246 | ||
| Allergic Contact Dermatitis | 1246 | ||
| Background | 1246 | ||
| History | 1246 | ||
| Physical examination | 1246 | ||
| Differential diagnosis | 1246 | ||
| Diagnostic study/biopsy | 1247 | ||
| Treatment | 1247 | ||
| Irritant Contact Dermatitis | 1247 | ||
| Background | 1247 | ||
| History | 1247 | ||
| Physical examination | 1247 | ||
| Atopic Dermatitis | 1269 | ||
| Key points | 1269 | ||
| PATIENT HISTORY/SYMPTOMS | 1269 | ||
| PATHOPHYSIOLOGY | 1270 | ||
| PHYSICAL EXAMINATION | 1270 | ||
| DIAGNOSTIC TESTS/IMAGING STUDIES | 1271 | ||
| DIFFERENTIAL DIAGNOSIS | 1273 | ||
| DIAGNOSTIC DILEMMAS | 1276 | ||
| TREATMENT | 1276 | ||
| Restoring the Skin Barrier | 1276 | ||
| Antiinflammatories | 1277 | ||
| Topical corticosteroids | 1277 | ||
| Topical calcineurin inhibitors | 1279 | ||
| Phototherapy | 1280 | ||
| Systemic immunosuppressants | 1280 | ||
| Management of pruritus | 1280 | ||
| External environmental factors | 1282 | ||
| Skin infection | 1283 | ||
| OTHER MANAGEMENT CONSIDERATIONS | 1284 | ||
| REFERENCES | 1284 | ||
| FURTHER READINGS | 1285 | ||
| Rheumatologic Skin Disease | 1287 | ||
| Key points | 1287 | ||
| LUPUS ERYTHEMATOSUS | 1287 | ||
| Patient History | 1287 | ||
| Clinical Findings | 1288 | ||
| Acute cutaneous lupus | 1288 | ||
| Subacute cutaneous lupus | 1289 | ||
| Discoid cutaneous lupus | 1290 | ||
| Variations of lupus skin findings | 1290 | ||
| Treatment | 1291 | ||
| Future Therapy | 1292 | ||
| DERMATOMYOSITIS | 1292 | ||
| Patient History | 1293 | ||
| Clinical Findings | 1293 | ||
| Treatment | 1296 | ||
| Future Therapy | 1296 | ||
| MORPHEA | 1297 | ||
| Patient History | 1297 | ||
| Clinical Findings | 1297 | ||
| Plaque morphea | 1297 | ||
| Generalized plaque morphea | 1297 | ||
| Pansclerotic morphea | 1297 | ||
| Linear morphea | 1298 | ||
| Treatment | 1299 | ||
| Future Therapy | 1300 | ||
| REFERENCES | 1300 | ||
| Common Dermatologic Procedures | 1305 | ||
| Key points | 1305 | ||
| INTRODUCTION | 1305 | ||
| PATIENT PREPARATION | 1305 | ||
| SKIN ANESTHESIA | 1306 | ||
| BIOPSIES | 1306 | ||
| SHAVE BIOPSY | 1307 | ||
| PUNCH BIOPSY | 1309 | ||
| Special Considerations: Pigmented Lesions | 1310 | ||
| Postoperative Care | 1311 | ||
| Complications | 1311 | ||
| EXCISIONS | 1312 | ||
| CURETTAGE | 1312 | ||
| CRYOSURGERY | 1313 | ||
| INTRALESIONAL STEROID INJECTIONS | 1314 | ||
| ADVANCED DERMATOLOGIC PROCEDURES | 1315 | ||
| MOHS MICROGRAPHIC SURGERY | 1316 | ||
| ESTHETIC PROCEDURES | 1316 | ||
| Chemical Denervation | 1317 | ||
| Soft Tissue Augmentation | 1317 | ||
| Lasers | 1317 | ||
| Chemical Peels | 1318 | ||
| SUMMARY | 1319 | ||
| REFERENCES | 1319 | ||
| Skin Cancer Epidemiology, Detection, and Management | 1323 | ||
| Key points | 1323 | ||
| INTRODUCTION | 1323 | ||
| BASAL CELL CARCINOMA | 1324 | ||
| Epidemiology | 1324 | ||
| Detection | 1324 | ||
| Treatment | 1324 | ||
| SQUAMOUS CELL CARCINOMA | 1326 | ||
| Epidemiology | 1326 | ||
| Detection | 1326 | ||
| Treatment | 1328 | ||
| MELANOMA | 1328 | ||
| Epidemiology | 1328 | ||
| Detection | 1329 | ||
| Treatment | 1331 | ||
| OTHER CUTANEOUS NEOPLASMS | 1333 | ||
| SUMMARY | 1333 | ||
| REFERENCES | 1334 | ||
| Approach to the Patient with a Suspected Cutaneous Adverse Drug Reaction | 1337 | ||
| Key points | 1337 | ||
| INTRODUCTION | 1337 | ||
| RECOGNIZING COMPLICATED VERSUS UNCOMPLICATED CUTANEOUS ADVERSE DRUG REACTIONS | 1338 | ||
| ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS | 1341 | ||
| STEVENS-JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS | 1342 | ||
| DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS/DRUG-INDUCED HYPERSENSITIVITY SYNDROME | 1344 | ||
| ADDITIONAL MANAGEMENT CONSIDERATIONS | 1346 | ||
| SUMMARY | 1346 | ||
| REFERENCES | 1346 | ||
| Inpatient Consultative Dermatology | 1349 | ||
| Key points | 1349 | ||
| INTRODUCTION | 1349 | ||
| WHY INVOLVE DERMATOLOGY? | 1349 | ||
| Potential Cost Savings of Dermatology Involvement | 1350 | ||
| The Dermatologist as Teacher | 1350 | ||
| Barriers to Inpatient Consultation and the Dermatology Hospitalist Movement | 1350 | ||
| COMMON CONSULTATIONS SEEN BY THE INPATIENT DERMATOLOGIST | 1351 | ||
| Morbilliform Drug Eruptions | 1351 | ||
| Rash in the Hospitalized Immunosuppressed Patient | 1352 | ||
| Acute Graft-Versus-Host Disease | 1353 | ||
| Acute Graft-Versus-Host Disease in the Solid Organ Transplant Recipient | 1353 | ||
| Cutaneous Infections in the Immunosuppressed Patient: Herpes Group Infections | 1353 | ||
| Cutaneous Infections in the Immunosuppressed Patient: Opportunistic Fungal Infections | 1354 | ||
| Sweet Syndrome | 1357 | ||
| Contact Dermatitis | 1358 | ||
| Red Legs in the Hospitalized Patient: Cellulitis and Mimickers | 1359 | ||
| Mimics of lower extremity cellulitis: venous stasis dermatitis and lipodermatosclerosis | 1359 | ||
| Skin Ulcers in the Hospitalized Patient | 1359 | ||
| Calciphylaxis | 1360 | ||
| Pyoderma gangrenosum | 1361 | ||
| SUMMARY | 1361 | ||
| REFERENCES | 1361 | ||
| Teledermatology | 1365 | ||
| Key points | 1365 | ||
| INTRODUCTION | 1365 | ||
| TELEDERMATOLOGY MODALITIES | 1366 | ||
| STORE AND FORWARD | 1366 | ||
| Real-Time Interactive | 1367 | ||
| Hybrid | 1367 | ||
| DIAGNOSTIC RELIABILITY AND ACCURACY | 1367 | ||
| Reliability of Teledermatology Modalities | 1368 | ||
| Store and forward | 1368 | ||
| Real-time interactive | 1369 | ||
| Accuracy of Teledermatology Modalities | 1369 | ||
| Store and forward | 1369 | ||
| Real-time interactive | 1370 | ||
| DERMATOLOGY CLINIC VISITS AVERTED | 1370 | ||
| Store and Forward | 1370 | ||
| Real-Time Interactive | 1371 | ||
| CLINICAL OUTCOMES | 1371 | ||
| Store and Forward | 1371 | ||
| Real-Time Interactive | 1372 | ||
| PATIENT AND REFERRING CLINICIAN SATISFACTION | 1372 | ||
| Patient Satisfaction: Store and Forward | 1372 | ||
| Referring Clinician Satisfaction: Store and Forward | 1372 | ||
| Patient Satisfaction: Real-Time Interactive | 1374 | ||
| Referring Clinician Satisfaction: Real-Time Interactive | 1374 | ||
| FUTURE CONSIDERATIONS/SUMMARY | 1375 | ||
| REFERENCES | 1375 | ||
| Index | 1381 |